T ranscatheter aortic valve implantation (TAVI) has become the gold-standard treatment for patients unsuitable for surgical aortic valve replacement (sAVR). 1 Previous randomized trials have also proven their value in patients at high risk for sAVR, which has led to a rapid increase of TAVI procedures performed worldwide. 2, 3 Results from the PARTNER 2 trial (Placement of Aortic Transcatheter Valves 2) on intermediate-risk patients randomized to TAVI or sAVR have again demonstrated noninferiority for TAVI, with even a higher survival in patients feasible for a transfemoral (TF) approach. 4 These trials were performed with the SAPIEN and SAPIEN XT transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, CA).
Although randomized trials are excellent in assessing the value of a new technology in a selected cohort suitable for direct comparison with the gold-standard treatment, as in the case of TAVI versus sAVR, they do not provide information on the results achievable with a new technology in larger patient populations and daily practices. Thus, the SOURCE (SAPIEN Aortic Bioprosthesis European Outcome) family of registries were initiated in 2007 with the SOURCE Registry, a postapproval registry on the use of the SAPIEN THV (Edwards Lifesciences) to observe safety and performance of this THV under realworld conditions. 5 In recent years, THV technology in general and the SAPIEN prosthesis in particular were further developed to address shortcomings of TAVI identified in early studies. The SAPIEN 3, the latest generation of this balloonexpandable THV, contains modifications that could potentially improve implantation, facilitate TF access, and reduce strokes, vascular complications, and paravalvular leakages. The 30-day results of the first 150 patients treated were used to gain approval from European authorities and have been reported previously. 6, 7 Data on the experience of the SAPIEN 3 postmarketing approval were collected in Europe and North America at the same time. The results of the North American registry, with a design similar to SOURCE 3, and the outcomes of a propensity-matched comparison with sAVR were recently published. 8, 9 We now present the patient and procedural characteristics and 30-day outcomes of the SOURCE 3 Registry, the European postapproval multicenter and observational registry with the SAPIEN 3.
METHODS Registry Design and Purpose of This Report
In this article, we present the 30-day outcome of patients who underwent TAVI with a SAPIEN 3 in Europe after postmarked approval and were enrolled in the SOURCE 3 Registry. This in particular includes data on THV implantation and outcomes such as stroke, vascular complications, and paravalvular leakage.
The study was supervised by the SOURCE 3 Registry administration (online-only Data Supplemental) and approved by the institutional review boards of the participating centers (online-only Data Supplement), and all participants gave written informed consent.
THV and Delivery Devices
The SAPIEN 3 contains bovine pericardial leaflets that are mounted inside a cobalt-chromium alloy frame. An external polyethylene terephthalate fabric seal was added to the stent frame.
The prosthesis is delivered via the TF route with the Commander delivery catheter (Edwards Lifesciences), which is compatible with 14F (23 and 26 mm) and 16F (29 mm) expandable introducer sheaths. The Certitude delivery catheter (Edwards Lifesciences) can be used for TAVI using the transapical, transaortic, transcarotid, and subclavian approaches and is implanted through 18F (23 and 26 mm) or 21F (29 mm) sheaths. Both delivery systems contain an integrated nose cone on the tip of the catheter.
Definitions and Data Collection
All data were entered in the electronic data capture system by the participating centers and monitored by Edwards Lifesciences.
Clinical Perspective
What Is New?
• The 30-day results of the SOURCE 3 Registry (SAPIEN Aortic Bioprosthesis European Outcome) demonstrate that transcatheter aortic valve implantation with the SAPIEN 3 results in high procedural success with low procedural complications and excellent postimplantation hemodynamics.
• Moderate to severe paravalvular leakage appears to be lower with the SAPIEN 3 than with prior versions of this transcatheter heart valve.
• Rates of pacemaker implantation are higher with the SAPIEN 3 than with earlier generations of this valve.
• This, in combination with the growing experience of patient selection, procedure planning, execution, and postoperative care, has led to one of the best short-term outcomes ever reported after transcatheter aortic valve implantation.
What Are the Clinical Implications?
• These results demonstrate favorable outcomes with this third-generation transcatheter heart valve in clinical practice; they could serve as a benchmark for future studies.
• Although these findings may encourage heart teams to consider broader indications for transcatheter aortic valve implantation, future trials are needed to identify the patient population that benefits most from this technique.
• How transcatheter aortic valve implantation will benefit patient outcome in the long term remains to be seen.
Patients are assessed at discharge, after discharge (30 days), at 1 year, and annually up to 5 years after implantation. All study end points were defined per the VARC-2 (Valve Academic Research Consortium 2) criteria. Implantation success was defined as 1 valve implanted at the intended site by 1 attempted procedure. Outcomes measured in the SOURCE 3 Registry were all-cause death, cardiac death, stroke, major vascular complications, life-threatening bleeding, acute kidney injury, permanent pacemaker insertion, procedural complications, functional status, and echocardiographic assessment of valve function. Review and adjudication of key clinical events in the electronic database were performed by an independent clinical events committee. All echocardiographic data were site reported. All data used in the analysis were as of July 11, 2016 , and this has resulted in minor variations in the outcomes reported in this publication compared with the original presentation of the data by Wendler et al at EuroPCR 2016.
Statistical Analysis
Continuous variables are presented as mean±SD or median (quartiles 1 and 3) and were compared between groups with 2-sample t tests or Wilcoxon rank-sums tests. Categorical variables are given as frequencies and percentages and were compared by Fisher exact tests.
Thirty-day survival is based on days past the valve implantation, without consideration of discharge from hospital. The proportion of patients censored before 30 days is <1%, and pure proportion and Kaplan-Meier estimates of 30-day survival differ by ≈0.1%. For ease of presentation and computation, 30-day survivals were evaluated as pure proportions except when otherwise stated.
All statistical analysis was performed with SAS, version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS

Demographics and Baseline Characteristics
A total of 1950 patients from 80 centers in 10 countries were enrolled between July 2014 and October 2015. Three patients were excluded from the registry. One withdrew consent, and in 2 patients, no SAPIEN 3 was used during the procedure. Therefore, a total of 1947 patients who underwent TAVI with a SAPIEN 3 make up the final study cohort of the SOURCE 3 Registry (Figure 1) . Details of their demographic and baseline characteristics are shown in Table 1 , and completeness of data is presented in Table I in the online-only Data Supplement. The mean age was >81.6±6.6 years, and major comorbidities were frequent, resulting in a mean logistic EuroSCORE I (logES) of 18.3±13.2%. Of these, 28.9% (n=516) according to their logES of <10% would be considered intermediate-risk patients.
TF access was used in a total of 1695 patients (87.1%), whereas 252 patients (12.9%) underwent TAVI through a non-TF approach. The access routes chosen in this group were transapical (72%), transaortic (21%), transcarotid (4%), or transsubclavian (3%; Figure 1 ).
A comparison of baseline characteristics of these 2 groups showed that TF patients were older (mean age, 81.7±6.7 versus 80.8±6.4 years; P=0.048) and more often female (49.3% versus 40.1%; P=0.0068). Non-TF patients were more often affected by cardiac and noncardiac comorbidities, resulting in higher mean logES in non-TF patients (21.8% versus 17.8%; P<0.0001). In addition, TF patients presented more often with logESs <10 (30.5% versus 18.6%; P<0.0001), whereas non-TF patients were more frequently found to have a logES of >30 (24.7% versus 14.5%; P<0.0001; Table 1 ).
Procedural Data
A total of 1961 SAPIEN 3 valves were implanted, including 14 patients (0.7%) who needed a second SAPIEN 3 at the time of the TAVI procedure. The most common valve size used was 26 mm (41.2%), followed by 23 mm (36.3%) and 29 mm (22.5%; Table 2 ).
Most patients (n=1917, 98.5%) underwent TAVI treatment for native aortic valve stenosis, whereas 1.6% of patients (n=30) presented with failing aortic valve bioprostheses and received valve-in-valve therapy. In 59.9% of TF patients (n=1014), the procedure was performed under conscious sedation; the remaining cohort was intervened under general anesthesia. Pre-TAVI balloon valvuloplasty was used in only 50.6% of patients (TF, 54%; non-TF, 28.2%; P<0.0001).
Imaging and assessment of the aortic valve, left ventricle, and aortic root before the TAVI procedure were facilitated with transthoracic (n=1578, 81.1%) or trans- esophageal (n=311, 16%) echocardiography and cardiac computed tomography (n=1607, 82.5%).
Implantation success was high at 98.3% and not different between the 2 access groups (TF, 98.9%; non-TF, 97.7%). Post-TAVI dilation was performed in 10.4% of TF and 12.7% of non-TF patients (P=NS). As a result, average procedure times, measured as skin-to-skin times, were significantly shorter in TF patients compared with non-TF patients (69.9±33.8 versus 89.3±47.4 minutes; P<0.0001), whereas fluoroscopy time (8.2±7.5 versus 14.8±7.1 minute) and contrast volume (87.7±52.5 versus 125.7±59.2 mL) were significantly lower in the non-TF cohort (P<0.0001). Vascular closure was achieved with a percutaneous closure device in most TF patients (93.7%).
Procedural Events
Procedural complications were rare and not significantly different between the 2 access groups, with unplanned valve-in-valve procedures needed in 0.7%, conversion to open surgery with sAVR in 0.6%, cardiopulmonary bypass in 0.7%, and coronary obstruction and annular rupture reported in 0.4% and 0.2% of patients, respectively (Table 3) .
Patients who underwent TF TAVI were less often ventilated after they left the procedural theater compared with non-TF patients (3.5% versus 19.4%; P<0.0001; Table 3 ).
Antiplatelet/Antithrombotic Management
Although we do not have detailed information on the duration and specific antiplatelet agents used, 34.3% of patients were on a single antiplatelet agent, 25.3% were on dual antiplatelet therapy, 10.3% were only on anticoagulation treatment, 14.6% were on a combination of antiplatelet and anticoagulation therapy, and 8.9% were on none of these medications; in 6.4%, this information was not provided. (Figure 2 ).
Adverse Events
All-cause mortality was lower in the TF than non-TF group (1.9% versus 4.0%; P=0.0023). Total cardiovascular mortality was 1.1% and not significantly different between TF and non-TF access (Table 3) . No 30-day mortality was observed in patients who needed cardiopulmonary bypass during the TAVI, but in those who were cardioverted to sAVR, mortality increased to 27% (3 of 11).
Causes of death were more often of cardiovascular nature in the TF cohort (66% versus 44%) and more often adjudicated toward intraprocedural complications (47% versus 22%). In the non-TF cohort, the majority of patient deaths were due to noncardiovascular reasons (56% versus 34%).
Strokes were reported in 28 patients (1.4%), of which 10 (0.5%) were disabling. The incidence was not different between the 2 access groups. Although major vascular complications (total, 4.1%) were also not different between the cohorts, life-threatening bleeding (9.6% versus 4.3%; P=0.0004) and new-onset postoperative atrial fibrillation (12.5% versus 4.8%; P<0.0001) were more common after non-TF TAVI. New permanent pacemakers were implanted in 12% of patients, in the majority of patients triggered by a complete atrioventricular blockage (159 of 233, 68.2%). Other commonly observed electrocardiographic changes included left-bundle-branch block (22.7%, n=53), atrioventricular blockage grade I (31 of 233, 13.3%) and grade II (17 of 233, 7.3%), and various other arrhythmias (33 of 233, 14.2%). Acute degree II to III kidney injury according to VARC-2 definitions was reported in 22 patients (1.1%) and was more frequent after non-TF access (3.2% versus 0.8%; P<0.0001). As a result, the median length of stay in the TF group was 7.0 days (interquartile range, 5-9 days) and thus shorter compared with the non-TF group (9 days; interquartile range, 7-13 days; P<0.0001; Table 3 ). Among patients considered to be intermediate risk with a logES of <10, the incidence of all-cause mortality was 1.7%; cardiovascular mortality, 1.1%; all strokes, 1.7%; major vascular complications, 3.8%; and new pacemaker implantation, 12.6%.
Functional Changes
Comparing preprocedural and postprocedural symptoms showed that the proportion of patients with New York Heart Association class III/IV symptoms in the TF group (73.9% to 10.4%, P<0.0001) and the non-TF group (69.8% to 28.0%, P<0.0001) decreased significantly (Figure 3 ).
DISCUSSION
The SOURCE 3 Registry is currently the largest data set on the use of the SAPIEN 3 THV, which received CE Mark approval in Europe in 2014. The 30-day results presented here confirm that its use under so-called real-world conditions provides excellent outcomes. Allcause mortality is lower for TF than non-TF access, but for the first time in a SOURCE Registry, cardiovascular mortality is not affected by access routes. The overall low mortality is likely a result of the low number of procedural and 30-day adverse events, including disabling stroke, as well as favorable hemodynamics, with a very low rate of more than mild paravalvular leakage (3.1%). The increase in implantation success, in previous investigations also referred to as procedural success, is likely a consequence of the modifications to the SA-PIEN 3 compared with previous models. The reduction in diameter of the introducer devices and their nose cones was developed to improve implantation, to facilitate TF access, and to reduce strokes and vascular complications. The sealing was mounted around the stent to reduce paravalvular leakage. However, it also needs to be recognized that heart teams have gained more experience in procedural planning and patient selection. In this respect, 3-dimensional imaging of the heart and aortic root such as 3-dimensional echocardiography 10 and cardiac computed tomography 11 has been a major step forward and is now implemented as routine diagnostics.
The first SOURCE Registry, for which enrollment started in 2007 and patients were treated with the SA-PIEN THV, 5 was followed by SOURCE XT, 12 which used second-generation (SAPIEN XT) prostheses. A comparison of the baseline characteristics of patients shows that over the last nearly 10 years, the mean age of patients included in the 3 registries has remained constant at ≈81 years (Table 4) . Nevertheless, the logES, an indicator of the patient risk profile, has reduced over time. Although this is particularly the case for TF patients, the logES for the non-TF cohort between SOURCE XT and SOURCE 3 remained unchanged and >21. These changes are a result of a reduced number of futile patients, with very high logESs, being treated, while at the same time the number of intermediate-risk patients in Europe, most often suitable for TF access, is rising. Nevertheless, final conclusions should not be drawn at this time. Future specific subanalyses are on their way to find answers to this and various other unanswered questions. Implantation success has improved over time and is most likely explained by additional clinical experience and improvements to the SAPIEN 3 itself. As a result, major vascular complications and the overall stroke rate in SOURCE 3 are the lowest reported in a SOURCE Registry. In this respect, the low profile and nose cone of the delivery systems, which also offer an additional opportunity to perform the procedure without predilation, may play a particular role. Given these baseline characteristics and procedural outcomes, it is interesting to see that all-cause 30-day mortality between SOURCE and SOURCE XT was quite static. Nevertheless, as shown above, SOURCE 3 results now show lower all-cause mortality for both access routes than has been reported with previous-generation devices and, for the first time, a cardiovascular 30-day mortality that is not different between access routes. Given the further reduction in clinically significant paravalvular leakage reported in SOURCE 3, it will be interesting to see how this translates to 1-year survival and beyond.
Compared with the SOURCE 3 Registry, the 30-day outcomes of the approval trial of the SAPIEN 3, including 150 patients, were similar in terms of low all-cause mortality (2.1%) and cardiac mortality (2.1%) in the TF cohort. 6 In contrast, non-TF access was still associated with higher mortality (all cause, 11.1%; cardiovascular, 9.3%). However, procedural success was as high (99%), and complications such as major vascular events for TF (4.2%), disabling strokes (zero), and more than mild paravalvular leakage (3.5%,) were as low as in SOURCE 3. 7 Others have also observed these procedural improvements between SAPIEN XT and SAPIEN 3 in smaller, but propensity-matched, cohorts. 13, 14 Like us, they found reduced major vascular complications and paravalvular leakage with the SAPIEN 3. However, in contrast to SOURCE 3, in which the permanent pacemaker rate increased compared with SOURCE XT (12% versus 6%), their rate of permanent pacemakers had been stable at ≈6% 14 and 9%. 13 This may support the hypothesis that the higher pacemaker rate with the SAPIEN 3 is a consequence of the implantation depth, which tends to be lower with the SAPIEN 3 prosthesis and not related to the device itself. Future trials specifically designed to answer this question should be considered.
At the same time, while data on outcomes with the SAPIEN 3 were collected in Europe, an all-comers registry, including inoperable/high-risk and intermediate-risk patients, comparable to SOURCE 3, enrolled patients in North America. 8 Interestingly, their 30-day results are similar to the results presented here. The dominant implantation route was TF (86.9%), and procedural com- plications were low. All-cause mortality was reported at 2.2% (high-risk patients) and 1.1% (intermediate-risk patients), whereas cardiovascular mortality was lowest in the intermediate-risk group (0.9% versus 1.4%). As in SOURCE 3, the difference in mortality between TF and non-TF was less than previously reported and nonexistent in the intermediate cohort. Hemodynamic results at 30 days were very similar to SOURCE 3, with a very low rate of paravalvular leakage (moderate degree, 3.4%; severe degree, none). The similarity in outcomes makes it likely that the SAPIEN 3 device has been improved to a level where the implantation has become less investigator dependent, an ultimate goal of any device used in medicine.
Implications
The excellent outcomes with the SAPIEN 3 reported here and the recently published propensity-matched comparison of intermediate-risk patients treated with the SAPIEN 3 with patients who underwent sAVR in PARTNER 2 9 may stimulate heart teams to consider TAVI in even lower-risk patients. Although this may be justified in elderly patients (mean age in most TAVI trials like the SOURCE Registries is ≈80 years), one should be careful in extrapolating these results to younger patients and other devices because their risk profile may be different.
For example, complications such as pacemaker implantations after TAVI have different consequences for younger patients. The risk of stroke may not decrease as much with lower age in TAVI as it decreases with age in surgery because the mechanisms of cerebral ischemia during the procedure are very different. In addition, durability is crucial when considering treating younger patients. Data beyond 10 years after THV implantation are currently not available, and in SOURCE 3, follow-up is planned for a total of 5 years. In the first instance, it would be safer to focus on elderly low-risk patients who benefit most from the advantages of TAVI, while they are not so much at risk from possible unknown consequences.
Limitations
The SOURCE 3 Registry is a clinical registry, and all outcomes are self-reported by the participating centers. The implanting teams made the decision about the access route, although it is acknowledged that the majority of participating centers perform TAVI via TF access if feasible. The participating centers committed to submit consecutive series of patients treated with the SAPIEN 3, but this was not controlled in detail.
Strokes are self-reported, and no routine neurological assessment was performed in all patients. However, all clinical events, including strokes, were adjudicated by an independent committee.
Conclusions
The 30-day results of the SOURCE 3 Registry demonstrate that TAVI with the SAPIEN 3 results in high procedural success with low procedural complications and excellent postimplantation hemodynamics. This, in combination with the growing experience of patient selection, procedure planning, execution, and postoperative care, has led to one of the best short-term outcomes ever reported after TAVI. These outcomes not only demonstrate the short-term advantages of this third-generation THV in clinical practice but also should be used as a benchmark for other THV devices entering the market.
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